Harrow, Inc. (NASDAQ:HROW) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Harrow, Inc. (NASDAQ:HROW) have been given a consensus recommendation of “Moderate Buy” by the ten brokerages that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation and eight have issued a buy recommendation on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $71.1429.

A number of equities analysts have commented on HROW shares. William Blair restated an “outperform” rating on shares of Harrow in a research note on Tuesday, March 3rd. Cantor Fitzgerald dropped their price target on Harrow from $94.00 to $91.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 4th. HC Wainwright raised their price target on Harrow from $69.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Zacks Research lowered Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a research note on Thursday, January 22nd.

Hedge Funds Weigh In On Harrow

Institutional investors have recently modified their holdings of the company. Blackhawk Capital Partners LLC acquired a new position in Harrow during the 3rd quarter valued at about $5,272,000. Divisadero Street Capital Management LP acquired a new stake in shares of Harrow in the second quarter valued at approximately $4,293,000. Brookstone Capital Management raised its holdings in shares of Harrow by 232.5% during the third quarter. Brookstone Capital Management now owns 45,775 shares of the company’s stock valued at $2,205,000 after buying an additional 32,009 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Harrow by 4.7% during the second quarter. Geode Capital Management LLC now owns 810,803 shares of the company’s stock worth $24,765,000 after buying an additional 36,724 shares during the period. Finally, Calamos Advisors LLC acquired a new position in shares of Harrow during the third quarter worth approximately $1,088,000. Institutional investors own 72.76% of the company’s stock.

Harrow Trading Down 4.1%

NASDAQ HROW opened at $34.10 on Friday. The company has a debt-to-equity ratio of 4.67, a quick ratio of 2.06 and a current ratio of 2.20. Harrow has a one year low of $20.85 and a one year high of $54.85. The company has a 50-day simple moving average of $46.23 and a 200-day simple moving average of $43.60. The firm has a market capitalization of $1.27 billion, a PE ratio of -200.58 and a beta of 0.05.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.